Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Gene therapy using adeno-associated viral (AAV) vectors currently represents the most promising approach for the treatment of many inherited retinal diseases (IRDs), given AAV’s ability to efficiently deliver therapeutic genes to both photoreceptors and retinal pigment epithelium, and their excellent safety and efficacy profiles in humans. However, one of the main obstacles to widespread AAV application is their limited packaging capacity, which precludes their use from the treatment of IRDs which are caused by mutations in genes whose coding sequence exceeds 5 kb. Therefore, in recent years, considerable effort has been made to identify strategies to increase the transfer capacity of AAV vectors. This review will discuss these new developed strategies, highlighting the advancements as well as the limitations that the field has still to overcome to finally expand the applicability of AAV vectors to IRDs due to mutations in large genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adjustments, such as 200-300 bp of specific compatible overhangs, have resulted in normal concatemerization of independent gene cassettes such as the hybrid dual rAAV approach [214].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [214]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An update on dual and triple rAAV vectors can be found in a recent paper by Trapani [214] who successfully applied a dual ABCA4 AAV vector system in Abca4 knockout mice [215,216].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“In this context, localized subretinal delivery of therapeutic transgenes has demonstrated efficient photoreceptor engagement using AAV5,7,8 and 9 [126].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [126]
In the citing paper
“The dual AAV vector system involves splitting the large transgene into two <5kb fragments that are packaged and co-delivered into the cell.”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [80]
In the citing paper
“The DNA fragments are then recombined into a complete functional transgene intracellularly either by homologous recombination or trans-splicing mechanisms [79,80,81].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [80]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150 · cited 1×
“First, in the retina, where homologous recombination occurs at low rates, genome editing tools for the precise correction of a mutation will most probably need to exploit alternative repair mechanisms such as non-homologous end joining used for homology-independent targeted integration [61].”
BackgroundEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Grieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398 · cited 1×
“Some studies have shown that use of capsid-engineered AAV variants with higher retinal transduction abilities, as tyrosine mutants capsids [39], led to higher levels of transgene expression from overlapping dual AAV vectors compared to naturally occurring AAV serotypes [20,33].”
Lai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J. S., Terjung, R. L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36612 · Cited by 389 · cited 1×
“, a minigene), has also been achieved with some success [58].”
BackgroundStargardt disease: clinical features, molecular genetics, animal models and therapeutic options
Tanna, P., Strauss, R. W., Fujinami, K., & Michaelides, M. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308823 · Cited by 370 · cited 1×
“The efficacy of both oversized and dual AAV vectors in the retina has been evaluated in a number of studies using different reporter and therapeutic genes, such as ABCA4 and MYO7A mutated in Stargardt disease (STGD1) [31] and Usher syndrome type 1B (USH1B) [32], respectively.”
BackgroundIn Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310 · cited 2×
“AAV5, AAV7, AAV8 and AAV9 serotypes have all been demonstrated to efficiently transduce photoreceptors [4,8].”
ResultTrans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305 · cited 2×
“The trans-splicing approach relies on the natural ability of AAV ITRs to concatemerize in order to reconstitute full-length genomes [22,25].”
BackgroundAllocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292 · cited 1×
“These “oversized” AAV vectors have been found to successfully express full-length proteins in vitro and in the retina of IRD models to levels which led to significant and stable improvement of the phenotype [12,15].”
BackgroundEffective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
Self-citationDuan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262 · cited 2×
“Various dual AAV vector strategies have been developed (referred to as trans-splicing [22], overlapping [23] and hybrid [24] dual AAV vector strategies), which differ in the mechanism they use to reconstitute the transgene.”
BackgroundDNA repair in neurons: So if they don’t divide what's to repair?
Fishel, M. L., Vasko, M. R., & Kelley, M. R. (2007) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2006.06.007 · Cited by 256 · cited 1×
“The targeted tissue also plays an important role in the success of the overlapping dual AAV approach since homologous recombination is typically associated with dividing cells, while low levels of homologous recombination are found in post-mitotic cells as neurons [34].”
BackgroundCharacterization of Genome Integrity for Oversized Recombinant AAV Vector
Dong, B., Nakai, H., & Xiao, W. (2010) · Molecular Therapy · doi:10.1038/mt.2009.258 · Cited by 230
Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae
Gilon, T. (1998) · The EMBO Journal · doi:10.1093/emboj/17.10.2759 · Cited by 227 · cited 1×
“destabilizing peptide that shares structural similarities with misfolded proteins and is thus recognized by the ubiquitination system [45,46].”
BackgroundEfficient in vivo gene expression by trans-splicing adeno-associated viral vectors
Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S., & Duan, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1153 · Cited by 224 · cited 1×
“An additional limiting step of trans-splicing vectors is splicing across the ITR junction, the efficiency of which is dependent on both selection of the optimal exon–exon junction for splitting the large therapeutic gene [27] as well as the efficiency of splicing across the ITR structure [28].”
BackgroundYang, J., Zhou, W., Zhang, Y., Zidon, T., Ritchie, T., & Engelhardt, J. F. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.9468-9477.1999 · Cited by 201 · cited 1×
“The trans-splicing approach relies on the natural ability of AAV ITRs to concatemerize in order to reconstitute full-length genomes [22,25].”
BackgroundUsher syndrome: Animal models, retinal function of Usher proteins, and prospects for gene therapy
Williams, D. S. (2008) · Vision Research · doi:10.1016/j.visres.2007.08.015 · Cited by 188 · cited 3×
“The efficacy of both oversized and dual AAV vectors in the retina has been evaluated in a number of studies using different reporter and therapeutic genes, such as ABCA4 and MYO7A mutated in Stargardt disease (STGD1) [31] and Usher syndrome type 1B (USH1B) [32], respectively.”
BackgroundChoi, J.-H., Yu, N.-K., Baek, G.-C., Bakes, J., Seo, D., Nam, H. J., Baek, S. H., Lim, C.-S., Lee, Y.-S., & Kaang, B.-K. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-17 · Cited by 188
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183 · cited 5×
“Indeed, following subretinal delivery, virtually all the AAV serotypes tested efficiently transduced the retinal pigment epithelium (RPE), while the levels of transduction of photoreceptors, which are the main therapeutic target cells in most IRDs, varied significantly among different serotypes [4,8].”
BackgroundMethodInfluentialSelf-citationEvidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb
Lai, Y., Yue, Y., & Duan, D. (2010) · Molecular Therapy · doi:10.1038/mt.2009.256 · Cited by 166
Ghosh, A., Yue, Y., Lai, Y., & Duan, D. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300322 · Cited by 161 · cited 12×
“The hybrid dual AAV approach is potentially more effective than the other dual AAV vector approaches, since full-length gene reconstitution can occur through both homologous recombination mediated by the highly recombinogenic exogenous sequence as well as concatemerization through the ITRs [24].”
InfluentialThe Status of RPE65 Gene Therapy Trials: Safety and Efficacy
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 150
Dyka, F. M., Boye, S. L., Chiodo, V. A., Hauswirth, W. W., & Boye, S. E. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.212 · Cited by 128
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128 · cited 4×
“triple AAV vectors have led to only a modest and transient improvement of the phenotype [38].”
BackgroundInfluentialSeeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124 · cited 2×
“The eye is an ideal target for gene therapy thanks to its small and enclosed structure, relative immune privilege and easy accessibility [1,2].”
BackgroundSelf-citationRetinal gene therapy with a large MYO7A cDNA using adeno-associated virus
Lopes, V. S., Boye, S. E., Louie, C. M., Boye, S., Dyka, F., Chiodo, V, Fofo, H., Hauswirth, W. W., & Williams, D. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.3 · Cited by 112 · cited 6×
“One study, as an example, relied on the use of overlapping dual AAV vectors with a large region of overlap (1365 bases) that had not been optimized and, therefore, might potentially have a low efficiency of recombination [15].”
BackgroundMethodResultInfluentialYan, Z., Zak, R., Zhang, Y., & Engelhardt, J. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.364-379.2005 · Cited by 107 · cited 10×
“The hybrid dual AAV approach is potentially more effective than the other dual AAV vector approaches, since full-length gene reconstitution can occur through both homologous recombination mediated by the highly recombinogenic exogenous sequence as well as concatemerization through the ITRs [24].”
InfluentialOstedgaard, L. S., Rokhlina, T., Karp, P. H., Lashmit, P., Afione, S., Schmidt, M., Zabner, J., Stinski, M. F., Chiorini, J. A., & Welsh, M. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409845102 · Cited by 105
Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors
Colella, P., Trapani, I., Cesi, G., Sommella, A., Manfredi, A., Puppo, A., Iodice, C., Rossi, S., Simonelli, F., Giunti, M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.8 · Cited by 103 · cited 3×
“A number of studies have indeed shown the ability of these strategies to reconstitute large transgenes in the retina [20,21,26,35,36] at levels which were higher compared to the other dual AAV strategies tested side by side [20,21,26], and which resulted in improvement of the retinal phenotype of animal models of IRDs…”
BackgroundResultSelf-citationReich, S. J., Auricchio, A., Hildinger, M., Glover, E., Maguire, A. M., Wilson, J. M., & Bennett, J. (2003) · Human Gene Therapy · doi:10.1089/10430340360464697 · Cited by 96
Ghosh, A., Yue, Y., & Duan, D. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.122 · Cited by 95 · cited 1×
“The recombinogenic sequences used thus far to induce the recombination between hybrid dual AAV vectors have been derived from regions of either the alkaline phosphatase gene (AP) [24,30] or the F1 phage genome (AK) [21].”
BackgroundTrapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E. V., Sommella, A., Colecchi, L., Rossi, S., Simonelli, F., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv386 · Cited by 94 · cited 5×
“A number of studies have indeed shown the ability of these strategies to reconstitute large transgenes in the retina [20,21,26,35,36] at levels which were higher compared to the other dual AAV strategies tested side by side [20,21,26], and which resulted in improvement of the retinal phenotype of animal models of IRDs…”
BackgroundResultInfluentialSelf-citationAn AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92
Gene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 89 · cited 2×
“For all the above described reasons, AAV have been used in many successful preclinical and clinical studies [3,4].”
BackgroundMethodAdeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 87
Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00503 · Cited by 86 · cited 9×
“A number of studies have indeed shown the ability of these strategies to reconstitute large transgenes in the retina [20,21,26,35,36] at levels which were higher compared to the other dual AAV strategies tested side by side [20,21,26], and which resulted in improvement of the retinal phenotype of animal models of IRDs…”
BackgroundResultInfluentialLittle Vector, Big Gene Transduction: Fragmented Genome Reassembly of Adeno-associated Virus
Hirsch, M. L., Agbandje-McKenna, M., & Jude Samulski, R. (2010) · Molecular Therapy · doi:10.1038/mt.2009.280 · Cited by 85
Yan, Z., Keiser, N. W., Song, Y., Deng, X., Cheng, F., Qiu, J., & Engelhardt, J. F. (2013) · Molecular Therapy · doi:10.1038/mt.2013.92 · Cited by 77 · cited 1×
“Alternatively, it has been shown that oversized AAV2 vector genomes can be effectively packaged in the capsid of human Bocavirus 1 (HBoV1) [49,50], an autonomous parvovirus relative of AAV, with a 5.”
BackgroundAdvances in AAV Vector Development for Gene Therapy in the Retina
Day, T. P., Byrne, L. C., Schaffer, D. V., & Flannery, J. G. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_86 · Cited by 71 · cited 3×
“AAV5, AAV7, AAV8 and AAV9 serotypes have all been demonstrated to efficiently transduce photoreceptors [4,8].”
BackgroundInfluentialVectors and Gene Delivery to the Retina
Planul, A., & Dalkara, D. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061413 · Cited by 67 · cited 1×
“This is one of the most attractive features of AAV vectors for retinal gene therapy, since alternative, both non-viral and viral, vectors tested thus far have shown more limited transduction abilities of adult photoreceptors [2,9].”
BackgroundYan, Z., Sun, X., Feng, Z., Li, G., Fisher, J. T., Stewart, Z. A., & Engelhardt, J. F. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.001 · Cited by 64 · cited 1×
“The combination of short synthetic enhancers and promoters was found to be useful for providing increased levels of expression of large transgenes [56].”
Oversized AAV Transductifon Is Mediated via a DNA-PKcs-independent, Rad51C-dependent Repair Pathway
Hirsch, M. L., Li, C., Bellon, I., Yin, C., Chavala, S., Pryadkina, M., Richard, I., & Samulski, R. J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.184 · Cited by 62 · cited 4×
“Whereas some studies found considerably high levels of transgene expression from oversized AAV vectors [14,15], others showed”
BackgroundInfluentialSpliceosome-Mediated RNA Trans-splicing
Yang, Y., & Walsh, C. E. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.006 · Cited by 59 · cited 1×
“Systems that rely on mechanisms different than those exploited by dual AAV vectors for large gene reconstitution might be investigated, including trans-splicing of pre-mRNAs [59] or intein-mediated protein trans-splicing [60].”
BackgroundSpecific tools for targeting and expression in Müller glial cells
Pellissier, L. P., Hoek, R. M., Vos, R. M., Aartsen, W. M., Klimczak, R. R., Hoyng, S. A., Flannery, J. G., & Wijnholds, J. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.9 · Cited by 58
FDA approves hereditary blindness gene therapy
(2018) · Nature Biotechnology · doi:10.1038/nbt0118-6a · Cited by 57
Fakhiri, J., Schneider, M. A., Puschhof, J., Stanifer, M., Schildgen, V., Holderbach, S., Voss, Y., El Andari, J., Schildgen, O., Boulant, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.003 · Cited by 56 · cited 1×
“Alternatively, it has been shown that oversized AAV2 vector genomes can be effectively packaged in the capsid of human Bocavirus 1 (HBoV1) [49,50], an autonomous parvovirus relative of AAV, with a 5.”
BackgroundXu, Z., Yue, Y., Lai, Y., Ye, C., Qiu, J., Pintel, D. J., & Duan, D. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.896 · Cited by 55
Split-inteins and their bioapplications
Li, Y. (2015) · Biotechnology Letters · doi:10.1007/s10529-015-1905-2 · Cited by 55 · cited 1×
“Systems that rely on mechanisms different than those exploited by dual AAV vectors for large gene reconstitution might be investigated, including trans-splicing of pre-mRNAs [59] or intein-mediated protein trans-splicing [60].”
BackgroundThe Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 52 · cited 1×
“The eye is an ideal target for gene therapy thanks to its small and enclosed structure, relative immune privilege and easy accessibility [1,2].”
BackgroundEfficacy of Codelivery of Dual AAV2/5 Vectors in the Murine Retina and Hippocampus
Palfi, A., Chadderton, N., McKee, A. G., Blanco Fernandez, A., Humphries, P., Kenna, P. F., & Farrar, G. J. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.142 · Cited by 42 · cited 2×
“This vector capacity is a critical issue, given the fact that approximately 6% of all human proteins have a coding sequence (CDS) that exceeds 4 kb [11] and that, in addition to the CDS of the therapeutic gene and the ITRs, a gene therapy vector needs to include, as a minimum, a promoter and a polyadenylation signal (…”
BackgroundYan, Z., Lei-Butters, D. C. M., Zhang, Y., Zak, R., & Engelhardt, J. F. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.128 · Cited by 41
Synthetic Intron Improves Transduction Efficiency of Trans -Splicing Adeno-Associated Viral Vectors
Lai, Y., Yue, Y., Liu, M., & Duan, D. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1036 · Cited by 37 · cited 1×
“To overcome the first issue, synthetic SD and SA signals have been developed, which mediate high rates of splicing independently of the gene that needs to be delivered [29].”
BackgroundEfficient CFTR expression from AAV vectors packaged with promoters – the second generation
Wang, D., Fischer, H., Zhang, L., Fan, P., Ding, R. X., & Dong, J. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300856 · Cited by 31
AAV Recombineering with Single Strand Oligonucleotides
Hirsch, M. L., Storici, F., Li, C., Choi, V. W., & Samulski, R. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007705 · Cited by 26 · cited 1×
“An additional strategy which has been used to direct AAV vectors concatemerization in the proper orientation is the use of a single-strand DNA oligonucleotide displaying homology to both of the distinct AAV genomes [43].”
MethodMcFarland, T. J., Zhang, Y., Atchaneeyaskul, L.-O., Francis, P., Stout, J. T., & Appukuttan, B. (2006) · Plasmid · doi:10.1016/j.plasmid.2005.11.005 · Cited by 26
Holehonnur, R., Lella, S. K., Ho, A., Luong, J. A., & Ploski, J. E. (2015) · Molecular Brain · doi:10.1186/s13041-015-0100-7 · Cited by 25 · cited 1×
“Other studies have however shown that, despite optimization, some transgenes were more difficult than others to reconstitute from oversized AAV vectors when using short promoters [57].”
BackgroundMaddalena, A., Dell'Aquila, F., Giovannelli, P., Tiberi, P., Wanderlingh, L. G., Montefusco, S., Tornabene, P., Iodice, C., Visconte, F., Carissimo, A., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.220 · Cited by 16
253. Expanded Packaging Capacity of AAV by Lumenal Charge Alteration
Tiffany, M., & Kay, M. A. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)33062-3 · Cited by 4 · cited 1×
“Attempts at identifying AAV vectors with expanded cargo capacity, based on either protein libraries and directed evolution [47] or site directed mutagenesis to add positively-charged residues at lumenally exposed sites within the capsid [48], have been described.”
(2014) · Molecular Therapy · doi:10.1016/s1525-0016(16)35319-9 · Cited by 2
Cited by
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
“With dual AAV technology, cDNA fragments that exceed the cargo capacity of a single AAV can be split into two halves and each packaged into a separate AAV, with additional sequences that allow reconstitution of the complete cDNA once inside the target cell (Trapani, 2019).”
BackgroundGhosh, S., Brown, A. M., Jenkins, C., & Campbell, K. (2020) · Applied Biosafety · doi:10.1177/1535676019899502 · Cited by 218
Gene regulatory programmes of tissue regeneration
Goldman, J. A., & Poss, K. D. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0239-7 · Cited by 200
Usher syndrome: clinical features, molecular genetics and advancing therapeutics
Toms, M., Pagarkar, W., & Moosajee, M. (2020) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841420952194 · Cited by 133
Gene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
“Therefore, in recent years, considerable effort has been made to identify strategies to increase the transfer capacity of AAV vectors [62].”
Background
Metadata
- Authors
- Trapani, I.
- Affiliations
- Federico II University Hospital (IT)
- Corresponding author
- Trapani, Ivana
- ORCID
- Trapani, Ivana
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2019-04-09
- Volume
- 10
- Issue
- 4
- Pages
- 287
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC6523333
- OpenAlex
- W2939601796
- Cited by
- 73
- References
- 62
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 9 · 2023: 8 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 4
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Università degli Studi di Napoli Federico II (STAR programme)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, gene therapy, inherited retinal disease, photoreceptors, retinal pigment epithelium
- MeSH terms
- Dependovirus, Genetic Vectors, Humans, Photoreceptor Cells, Retina, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.